Palvella Therapeutics (PVLA) Cash from Operations (2016 - 2024)
Historic Cash from Operations for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to -$5.4 million.
- Palvella Therapeutics' Cash from Operations fell 12617.99% to -$5.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$10.8 million, marking a year-over-year increase of 2118.51%. This contributed to the annual value of -$10.8 million for FY2024, which is 2118.51% up from last year.
- Per Palvella Therapeutics' latest filing, its Cash from Operations stood at -$5.4 million for Q4 2024, which was down 12617.99% from -$2.7 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Cash from Operations registered a high of $29.9 million during Q2 2021, and its lowest value of -$22.6 million during Q1 2022.
- Moreover, its 5-year median value for Cash from Operations was -$10.4 million (2020), whereas its average is -$6.9 million.
- Its Cash from Operations has fluctuated over the past 5 years, first surged by 40584.99% in 2021, then crashed by 15208.99% in 2022.
- Over the past 5 years, Palvella Therapeutics' Cash from Operations (Quarter) stood at -$13.4 million in 2020, then grew by 18.43% to -$10.9 million in 2021, then fell by 18.17% to -$12.9 million in 2022, then skyrocketed by 258.1% to $20.4 million in 2023, then plummeted by 126.18% to -$5.4 million in 2024.
- Its Cash from Operations stands at -$5.4 million for Q4 2024, versus -$2.7 million for Q3 2024 and -$1.6 million for Q2 2024.